Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies

PET Clin. 2015 Oct;10(4):461-76. doi: 10.1016/j.cpet.2015.05.005. Epub 2015 Jul 3.

Abstract

This review provides practical guidance for clinicians involved in the management of endocrine malignancies, including endocrinologists, medical oncologists, surgeons and nuclear medicine specialists regarding the indications and use of 2-fluoro-2-deoxy-d-glucose F-18 (FDG) PET/computed tomography (CT), particularly with respect to targeted radionuclide therapy. Key principles of FDG PET/CT for radionuclide therapy are explored in detail using gastroenteropancreatic neuroendocrine tumors as a prototype endocrine malignancy. The relevant literature is reviewed, and practical application in this new and emerging field is highlighted with the use of case examples.

Keywords: FDG PET/CT; Neuroendocrine tumor; Peptide receptor radionuclide therapy; Radionuclide therapy; Thyroid cancer.

Publication types

  • Review

MeSH terms

  • Endocrine Gland Neoplasms / diagnosis*
  • Endocrine Gland Neoplasms / radiotherapy*
  • Evidence-Based Medicine
  • Fluorodeoxyglucose F18*
  • Humans
  • Multimodal Imaging / methods
  • Patient Selection
  • Positron-Emission Tomography / methods*
  • Prognosis
  • Radiopharmaceuticals / therapeutic use*
  • Radiotherapy, Image-Guided / methods
  • Tomography, X-Ray Computed / methods*
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18